Testing Psychotherapies and Drug Therapies: The Case of Psychedelic Drugs

  • James B. Bakalar
  • Lester Grinspoon
Part of the Topics in the Neurosciences book series (TNSC, volume 9)

Abstract

The drug revolution that began 30 years ago has transformed psychiatry, but it has left little imprint on psychotherapeutic procedures themselves. Little attention has been given to the possibility of using drugs directly to enhance the process of psychotherapy — fortifying the therapeutic alliance and facilitating the production of memories, fantasies, and insights. A change may now be coming; for example, a psychiatrist known for his research on the therapeutic alliance has proposed that a “pharmacotherapy of interpersonal processes” might be considered both to study and to improve the alliance [1], The wait has been long partly because the research involved is complex and hard to perform. The theoretical bases for the two types of therapy are vastly different; these differences are reflected in the way experiments arc conducted and the results are evaluated. Reconciliation and unification will not be easy to achieve. One of the best ways to see why that is so is to examine the different significance assigned to placebo effects in drug experiments and psychotherapy studies.

Keywords

Placebo Depression Europe Lithium Aspirin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Docherty, J.P.. 1985. Introduction to Section V: The Therapeutic Alliance and Treatment Outcome. In The American Psychiatric Association Annual Review, Vol IV, ( Hales R E. and Frances A.J.. eds) New York: American Psychiatric PressGoogle Scholar
  2. 2.
    Garfield. S ., 1984 Psychotherapy: Efficacy. generality, and specificity In Psychotheraphy Research: Where are we and Where Should We Go? (Williams JB. and Spitzer RL.. eds.) New York Guilford PressGoogle Scholar
  3. 3.
    Klein, D.F.. 1983. Talking often helps: The efficacy, generality, and specificity of psychotherapy. Biol. Psychiat.. 18: 1101–1105.Google Scholar
  4. 4.
    Prioleau, L-. Murdock, M., and Brody. N.. 1983. An analysis of psychotherapy versus placebo studies. Behav. Brain Sci. 6. 275–310.Google Scholar
  5. 5.
    Strupp. H.H., 1986. Psychotherapy: Research, practice, and public policy. (How to avoid dead ends). Am. Psychol. 41: 120–130.PubMedCrossRefGoogle Scholar
  6. 6.
    Wilkins, W., 1986. Placebo problems in psychotherapy research: Social-psychological alternatives to chemotherapy concepts. Am. Psychol. 41: 551–556.PubMedCrossRefGoogle Scholar
  7. 7.
    Grunbaum, A.. 1981. The placebo concept. Behav. Res. Ther. 19: 157–167.PubMedCrossRefGoogle Scholar
  8. 8.
    Grunbaum, A., 1985. Explication and implications of the placebo concept. In Placebo: Theory. Research, and Mechanisms ( White. L.. Tursky. B.. and Schwartz. G.E.. eds). New York: Guilford Press.Google Scholar
  9. 9.
    Frank. J.D., 1973. Persuasion and Healing: A Comparative Study of Psychotherapy. Second Edition. Baltimore, MD: Johns Hopkins University Press.Google Scholar
  10. 10.
    Smith. M L., Glass. G.V.. and Miller. T.I.. 1980. The Benefits of Psychotherapy. Baltimore,MD: Johns Hopkins University Press.Google Scholar
  11. 11.
    Elkin. I.. Parloffi M B.. Hadlcy, S.W., et al., 1985. NIMH treatment of depression collaborative research program: Background and research plan. Arch. Gen. Psychiat. 42305–316.Google Scholar
  12. 12.
    Elkin. I., Shea. T., Imber, S.. et al., 1986. NIMH treatment of depression collaborative research program: Initial outcome findings abstract. American Association for the Advancement of Science. May.Google Scholar
  13. 13.
    Epstein. P. and Fawcett. J. Treatment of Depression Collaborative Research Program. Pharmacotherapy Training Site. Addendum to Clinical-Management-lmipramine-Placebo Administration Manual. Rush Presbyterian. St. Luke’s Medical Center. Dept. of Psychiatry.Google Scholar
  14. 14.
    Gomes-Schwartz. B.. 1978. Effective ingredients in psychotherapy: Prediction of outcome from process variables. J. Consult. Clin. Psychol. 46: 1023–1035.PubMedCrossRefGoogle Scholar
  15. 15.
    Moras, K. and Strupp. H.H.. 1982. Pretherapy interpersonal relations, patients’ alliancc. and outcome in brief therapy. Arch. Gen. Psychiat. 39: 405–412.PubMedGoogle Scholar
  16. 16.
    Albaugh, B.J. and Anderson. P.O.. 1974. Peyote in the treatment of alcoholism among American Indians. Am. J. Psychiat. 131: 1247–1251.PubMedGoogle Scholar
  17. 17.
    Grinspoon. L. and Bakalar. J.B., 1979. Psychedelic Drugs Reconsidered. New York: Basic Books.Google Scholar
  18. 18.
    Strassman, R.J.. 1984. Adverse reactions to psychedelic drugs: A review of the literature. J. Nerv. Ment. Dis. 172: 577–595.PubMedCrossRefGoogle Scholar
  19. 19.
    Shulgui. A.T.. 1983. Twenty years on an ever-changing quest. In Psychedelic Reflections ( Grinspoon, L. and Bakalar. J., eds.). New York Human Sciences Press.Google Scholar
  20. 20.
    Riedlinger. J.E.. 1985. A pharmacist’s perspective in the matter of MDMA scheduling. J. Psychoactive Drugs 17: 167–172.PubMedGoogle Scholar
  21. 21.
    Smith. D.E.. Wesson. D R. and Buffum. J.. 1985 MDMA: “Ecstasy” as an adjunct to psychotherapy and a street drug of abuse California Society for the Treatment of Alcoholism and Other drug Dependencies News 12: 2: 1–3.Google Scholar
  22. 22.
    Grinspoon. L. and Bakalar. J B.. 1986 Can drugs be used to enhance the psychotherapeutic process? Am. J. Psychother. 40: 393–404PubMedGoogle Scholar
  23. 23.
    Ludwig. A.M.. Levine. J., and Stark. L.H.. 1970. LSD and Alcoholism: A Clinic Study of Treatment Efficacy. Springfield, IL: Charles C. Thomas.Google Scholar
  24. 24.
    Hollister, L.E., Shelton. J., and Krieger. G.. 1969. A controlled comparison of lysergic acid duthylamide (LSD) and dextroamphetamine in alcoholics. Am. J Psychiat 125: 1352–1357PubMedGoogle Scholar
  25. 25.
    Kurland, A.. Savage, C.. Pahuke. W.. Grof. S. and Obsor. J E. 1971. LSD in the treatment of alcoholics. Pharmakopsychiat. Neuropharm. 4: 83–94Google Scholar
  26. 26.
    Cheek. F.E.. Osmond. H.. Sarett. M.. et al.. 1966. Observations regarding the use of LSD-25 in the treatment of alcoholism. J. Psychopharm. 1: 56–74.Google Scholar
  27. 27.
    Soskin, R.A.. 1973. The use of LSD in time-limited psychotheray J. Nerv. Men. Dis 157: 410–419.CrossRefGoogle Scholar
  28. 28.
    Abuzzahab Sr. F.S. and Anderson. B.J.. 1971. A review of LSD treatment in alcoholism Int Pharmacopsy 6: 223–235.Google Scholar
  29. 29.
    Yensen, R.. 1984. From mysteries to paradigms: Humanity’s journey from sacred plants to psychedelic drugs In Proceedings of the Association for the Responsible Use of Psychoactive Agents,, Esalen Institute. Big Sur, California. 1984 Albany, NT: State University of New York Presss, in pressGoogle Scholar
  30. 30.
    May, PR. A., 1968 Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods. New York: Science House.Google Scholar
  31. 31.
    Grinspoon. L., Ewalt, JR. and Shader, R.I, 1972. Schiziphrenia: Pharmacotherapy and Psychotherapy. Baltimore, MD: Williams and Wilkins.Google Scholar
  32. 32.
    Hartly. D.E., 1985 Research on the therapeutic alliance in psychotherapy. In The American Psychiatric Association Annual Review, Vol. IV ( Hales, R.E. and Frances, A.J., eds.). Washington. D.C.: American Psychiatric Press.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • James B. Bakalar
  • Lester Grinspoon

There are no affiliations available

Personalised recommendations